View Financial HealthPfizer 配当と自社株買い配当金 基準チェック /36Pfizerは配当を支払う会社で、現在の利回りは6.44%です。次の支払い日は 12th June, 2026で、権利落ち日は8th May, 2026 。主要情報6.4%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り6.6%配当成長4.0%次回配当支払日12 Jun 26配当落ち日08 May 26一株当たり配当金n/a配当性向126%最近の配当と自社株買いの更新Fourth quarter dividend of US$0.43 announced Apr 26Pfizer Inc. Declares Second-Quarter Cash Dividend on Common Stock for 2026, Payable June 12, 2026Apr 23+ 1 more updateUpcoming dividend of US$0.43 per share Jan 16Third quarter dividend of US$0.43 announced Dec 22Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026Dec 13Upcoming dividend of US$0.43 per share Nov 02すべての更新を表示Recent updatesPfizer Inc Announces Positive Topline Results from Phase 3 MagnetisMM-5 Study Evaluating Elrexfio as Monotherapy in Adults with Relapsed or Refractory Multiple MyelomaMay 01Pfizer Inc. Enters into Settlement Agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd for VYNDAMAXApr 30Fourth quarter dividend of US$0.43 announced Apr 26Pfizer Inc. Declares Second-Quarter Cash Dividend on Common Stock for 2026, Payable June 12, 2026Apr 23+ 1 more updateAstellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder CancerApr 20Pfizer Inc. to Report Q1, 2026 Results on May 05, 2026Mar 24Pfizer Inc. and Valneva SE Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor TrialMar 23Pfizer Inc Announces Positive Topline Results From Phase 3 Talapro-3 Study Of Talzenna In Combination With XtandiMar 19Pfizer Inc., Annual General Meeting, Apr 23, 2026Mar 13Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic DermatitisMar 10Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical TrialFeb 28Pfizer Inc. Announces U.S. FDA Grants Full Approval to its BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal CancerFeb 25Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal CancerFeb 17Pfizer Inc. Announced That FDA Has Accepted and Granted Priority Review for the Company's Supplemental Biologics License ApplicationFeb 06Full year 2025 earnings released: EPS: US$1.36 (vs US$1.42 in FY 2024) Feb 05Full year 2025 earnings released: EPS: US$1.36 (vs US$1.42 in FY 2024) Feb 04Pfizer Inc. Reaffirms Earnings Guidance for the Full Year 2026Feb 03+ 1 more updateUpcoming dividend of US$0.43 per share Jan 16Pfizer Inc.'s BRAFTOVI Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal CancerJan 12Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin PapantonioJan 08New major risk - Revenue and earnings growth Jan 01Third quarter dividend of US$0.43 announced Dec 22Pfizer Inc. to Report Q4, 2025 Results on Feb 03, 2026Dec 19Astellas Pharma Inc. and Pfizer Inc. Announces Positive Topline Results from an Interim Analysis of the Phase 3 EV-304 Clinical TrialDec 17+ 2 more updatesPfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026Dec 13Pfizer Inc. Announces Detailed Results from the Phase 3 HER2CLIMB-05 Trial of the Tyrosine Kinase Inhibitor TUKYSA (Tucatinib)Dec 11Pfizer Inc. Presents Results from the Phase 3 BASIS Study Evaluating HYMPAVZI for Adults and AdolescentsDec 07U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder CancerNov 22Pfizer Inc. (NYSE:PFE) completed the acquisition of Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others.Nov 14Pfizer Reportedly Looks to Sell Stake in Pandemic Vaccine Partner BioNTechNov 13Third quarter 2025 earnings released: EPS: US$0.62 (vs US$0.79 in 3Q 2024) Nov 05Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025Nov 04Upcoming dividend of US$0.43 per share Nov 02Pfizer Inc. Receives Early Clearance from U.S. Federal Trade Commission for Metsera AcquisitionNov 01Pfizer Inc. and Astellas Pharma U.S. Inc. Announces Final Overall Survival Results from the Phase 3 EMBARK Study Evaluating XTANDIOct 20+ 2 more updatesPfizer Inc. Announces Positive Topline Results from the Phase 3 Her2climb-05 Trial of First-Line Combination Therapy with the Tyrosine Kinase Inhibitor Tukysa®?Oct 15Second quarter dividend of US$0.43 announced Oct 13Hearing Against Pfizer Set for 29 September in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin PapantonioSep 26Pfizer Inc. to Report Q3, 2025 Results on Nov 04, 2025Sep 23New major risk - Revenue and earnings growth Sep 23Pfizer Inc. (NYSE:PFE) agreed to acquire Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others for $5 billion.Sep 22+ 1 more updateArbutus Pharma Corp. and Genevant Sciences GmbH Provides Lawsuit UpdateSep 12Nastlaw LLC and Direct Purchaser Plaintiffs Announce Additional Settlements in Re Generic Pharmaceutical Pricing Antitrust LitigationSep 11Pfizer Inc. and BioNTech SE Announce Topline Data Demonstrating Robust Immune Response with Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 FormulaSep 08Olema Pharmaceuticals, Inc. Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerSep 03Enanta Pharmaceuticals, Inc. Files Patent Infringement Suit Against Pfizer Inc. in the Unified Patent Court of the European UnionAug 20New minor risk - Share price stability Aug 13PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After SurgeryAug 12Second quarter 2025 earnings released: EPS: US$0.51 (vs US$0.004 in 2Q 2024) Aug 06Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025Aug 05BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA VaccineJul 25Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control PillJul 24Upcoming dividend of US$0.43 per share Jul 18Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDIJul 10First quarter dividend of US$0.43 announced Jul 02First quarter dividend of US$0.43 announced Jun 28Pfizer Inc. Announces Positive Topline Phase 3 Results for Hympavzi™? in Hemophilia A or B with InhibitorsJun 26+ 1 more updateArvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast CancerJun 06Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6May 30Case Management Conference in the Depo-Provera Legal Action Against Pfizer IncMay 29Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2May 23+ 1 more updateNew minor risk - Insider selling May 13First quarter dividend of US$0.43 announced May 03First quarter 2025 earnings released: EPS: US$0.52 (vs US$0.55 in 1Q 2024) May 03Pfizer Inc. Reaffirms Earnings Guidance for the Year 2025Apr 29Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk Non-Muscle Invasive Bladder CancerApr 28+ 1 more updatePfizer Inc. Declares Second-Quarter 2025 Dividend, Payable on June 13, 2025Apr 24ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 At Increased Risk of DiseaseApr 17Pfizer Inc. Provides Update on Oral Glp-1 Receptor Agonist DanuglipronApr 14Entwistle & Cappucci LLP Files Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, IncApr 05European Commission Approves Pfizer's RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract DiseaseApr 01Pfizer Inc. to Report Q1, 2025 Results on Apr 29, 2025Mar 18Pfizer Inc., Annual General Meeting, Apr 24, 2025Mar 14Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical TrialMar 11Senior VP recently sold CL$61m worth of stock Mar 11Independent Director recently bought CL$472m worth of stock Feb 15Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate CancerFeb 14U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaFeb 13Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial CancerFeb 11Pfizer Inc. Provides Earnings Guidance for the Year 2025Feb 07+ 1 more updateFull year 2024 earnings released: EPS: US$1.42 (vs US$0.38 in FY 2023) Feb 05Pfizer’s Braftovi Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 Breakwater TrialFeb 03Pfizer Inc. Announces Positive Results from the Phase 3 Breakwater Trial Evaluating Braftovi® (Encorafenib) in Combination with Cetuximab and Mfolfox6Jan 27Upcoming dividend of US$0.43 per share Jan 17Pfizer Intends to Sell Approximately 700 Million Ordinary Shares in HaleonJan 15Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder CancerJan 10U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerDec 21配当金の支払いについて今日May 01 2026配当落ち日May 08 2026配当支払日Jun 12 202635 days 配当落ちから次の7 days 、次の配当を受け取るために購入する。決済の安定と成長配当データの取得安定した配当: PFECLの1株当たり配当金は過去10年間安定しています。増加する配当: PFECLの配当金は過去10年間にわたって増加しています。配当利回り対市場Pfizer 配当利回り対市場PFECL 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PFECL)6.4%市場下位25% (CL)0%市場トップ25% (CL)0%業界平均 (Pharmaceuticals)0%アナリスト予想 (PFECL) (最長3年)6.6%注目すべき配当: PFECLの配当金 ( 6.44% ) はCL市場の配当金支払者の下位 25% ( 2.35% ) よりも高くなっています。高配当: PFECLの配当金 ( 6.44% ) はCL市場の配当金支払者の上位 25% ( 6.63% ) と比較すると低いです。株主への利益配当収益カバレッジ: PFECLは高い 配当性向 ( 126.2% ) のため、配当金の支払いは利益によって十分にカバーされていません。株主配当金キャッシュフローカバレッジ: PFECLは高い 現金配当性向 ( 107.8% ) のため、配当金の支払いはキャッシュフローで十分にカバーされていません。高配当企業の発掘7D1Y7D1Y7D1YCL 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 03:17終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pfizer Inc. 26 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。44 アナリスト機関David ToungArgus Research CompanyEmily FieldBarclaysKerry HolfordBerenberg41 その他のアナリストを表示
Pfizer Inc. Declares Second-Quarter Cash Dividend on Common Stock for 2026, Payable June 12, 2026Apr 23+ 1 more update
Pfizer Inc Announces Positive Topline Results from Phase 3 MagnetisMM-5 Study Evaluating Elrexfio as Monotherapy in Adults with Relapsed or Refractory Multiple MyelomaMay 01
Pfizer Inc. Enters into Settlement Agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd for VYNDAMAXApr 30
Pfizer Inc. Declares Second-Quarter Cash Dividend on Common Stock for 2026, Payable June 12, 2026Apr 23+ 1 more update
Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder CancerApr 20
Pfizer Inc. and Valneva SE Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor TrialMar 23
Pfizer Inc Announces Positive Topline Results From Phase 3 Talapro-3 Study Of Talzenna In Combination With XtandiMar 19
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical TrialFeb 28
Pfizer Inc. Announces U.S. FDA Grants Full Approval to its BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal CancerFeb 25
Pfizer Inc. Announced That FDA Has Accepted and Granted Priority Review for the Company's Supplemental Biologics License ApplicationFeb 06
Pfizer Inc.'s BRAFTOVI Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal CancerJan 12
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Topline Results from an Interim Analysis of the Phase 3 EV-304 Clinical TrialDec 17+ 2 more updates
Pfizer Inc. Announces Detailed Results from the Phase 3 HER2CLIMB-05 Trial of the Tyrosine Kinase Inhibitor TUKYSA (Tucatinib)Dec 11
Pfizer Inc. Presents Results from the Phase 3 BASIS Study Evaluating HYMPAVZI for Adults and AdolescentsDec 07
Pfizer Inc. (NYSE:PFE) completed the acquisition of Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others.Nov 14
Pfizer Inc. Receives Early Clearance from U.S. Federal Trade Commission for Metsera AcquisitionNov 01
Pfizer Inc. and Astellas Pharma U.S. Inc. Announces Final Overall Survival Results from the Phase 3 EMBARK Study Evaluating XTANDIOct 20+ 2 more updates
Pfizer Inc. Announces Positive Topline Results from the Phase 3 Her2climb-05 Trial of First-Line Combination Therapy with the Tyrosine Kinase Inhibitor Tukysa®?Oct 15
Hearing Against Pfizer Set for 29 September in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin PapantonioSep 26
Pfizer Inc. (NYSE:PFE) agreed to acquire Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others for $5 billion.Sep 22+ 1 more update
Nastlaw LLC and Direct Purchaser Plaintiffs Announce Additional Settlements in Re Generic Pharmaceutical Pricing Antitrust LitigationSep 11
Pfizer Inc. and BioNTech SE Announce Topline Data Demonstrating Robust Immune Response with Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 FormulaSep 08
Olema Pharmaceuticals, Inc. Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerSep 03
Enanta Pharmaceuticals, Inc. Files Patent Infringement Suit Against Pfizer Inc. in the Unified Patent Court of the European UnionAug 20
PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After SurgeryAug 12
BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA VaccineJul 25
Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control PillJul 24
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDIJul 10
Pfizer Inc. Announces Positive Topline Phase 3 Results for Hympavzi™? in Hemophilia A or B with InhibitorsJun 26+ 1 more update
Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast CancerJun 06
Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6May 30
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2May 23+ 1 more update
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk Non-Muscle Invasive Bladder CancerApr 28+ 1 more update
ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 At Increased Risk of DiseaseApr 17
Entwistle & Cappucci LLP Files Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, IncApr 05
European Commission Approves Pfizer's RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract DiseaseApr 01
Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical TrialMar 11
Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate CancerFeb 14
U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaFeb 13
Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial CancerFeb 11
Pfizer’s Braftovi Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 Breakwater TrialFeb 03
Pfizer Inc. Announces Positive Results from the Phase 3 Breakwater Trial Evaluating Braftovi® (Encorafenib) in Combination with Cetuximab and Mfolfox6Jan 27
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder CancerJan 10
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerDec 21